Evidence map›Paper›PMID 34712552›Full record

ArticleAnalytical cellular pathology (Amsterdam)2021

FAT1 and PTPN14 Regulate the Malignant Progression and Chemotherapy Resistance of Esophageal Cancer through the Hippo Signaling Pathway.

Yingzhi Lu, Zhenxin Wang, Ling Zhou, Zhaoming Ma, Jianguo Zhang, Yan Wu, Yan Shao, Yunyun Yang

Open access · goldAbstract read
In one paragraph

Article in Analytical cellular pathology (Amsterdam), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. The diverse functions of FAT1 in cancer progression: good, bad, or ugly?Journal of experimental & clinical cancer research : CR · 2022
    Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yingzhi LuDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.
Zhenxin WangDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.ORCID https://orcid.org/0000-0001-8921-9081
Ling ZhouDepartment of Nephrology, The Second's Hospital of Lianyungang (The Oncology Hospital of Lianyungang), No 161, XinFu Road, Lianyungang, Jiangsu 222000, China.ORCID https://orcid.org/0000-0002-4068-3286
Zhaoming MaDepartment of Medical Oncology, The Second People's Hospital of Lianyungang (The Oncology Hospital of Lianyungang), No 161, XinFu Road, Lianyungang, Jiangsu 222000, China.
Jianguo ZhangDepartment of Medical Oncology, The Second People's Hospital of Lianyungang (The Oncology Hospital of Lianyungang), No 161, XinFu Road, Lianyungang, Jiangsu 222000, China.
Yan WuDepartment of Medical Oncology, The Second People's Hospital of Lianyungang (The Oncology Hospital of Lianyungang), No 161, XinFu Road, Lianyungang, Jiangsu 222000, China.
Yan ShaoDepartment of Medical Oncology, The Second People's Hospital of Lianyungang (The Oncology Hospital of Lianyungang), No 161, XinFu Road, Lianyungang, Jiangsu 222000, China.
Yunyun YangDepartment of Medical Oncology, The Second People's Hospital of Lianyungang (The Oncology Hospital of Lianyungang), No 161, XinFu Road, Lianyungang, Jiangsu 222000, China.
The First People’s Hospital of Lianyungang · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal cancer (EC) is a common malignant tumor, which brings heavy economic burden to patients and society. Therefore, it is important to understand the molecular mechanism of recurrence, metastasis, and drug resistance of esophageal cancer.

methodsHuman esophageal cancer cell line TE13 (poorly differentiated squamous cell carcinoma) and normal human esophageal epithelial cell line het-1a were selected for aseptic culture. At the same time, 6 bottles of TE13 cell line were inoculated in logarithmic phase. Cell apoptosis was analyzed by flow cytometry (FCM). Cell clone formation assay was used to analyze the proliferation. Fibronectin-coated dishes were used to detect the characteristics of cell adhesion to extracellular matrix. The Transwell method was used to detect the cell invasion ability. Western blot was used to analyze the expression of Yap1, PTPN14, FAT1, and Myc.

resultsResults showed that FAT1 and PTPN14 were downregulated, while Yap1 was upregulated in esophageal cancer tissues. FAT1 inhibited the proliferation, adhesion, and invasion of human esophageal cancer cell lines, which might be associated with the upregulation of PTPN14 and the inhibition of Yap1 and Myc.

conclusionThe results suggested that PTPN14 and FAT1 could regulate malignant progression and chemotherapy resistance of esophageal cancer based on the Hippo signaling pathway.

Indexed as

CadherinsDisease ProgressionDrug Resistance, NeoplasmEsophageal NeoplasmsHippo Signaling PathwayHumansProtein Tyrosine Phosphatases, Non-ReceptorCadherinsFAT1 protein, humanProtein Tyrosine Phosphatases, Non-ReceptorPTPN14 protein, human

Identifiers

PMID34712552
PMCPMC8548181
OpenAlexW3205175198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.